Evox Therapeutics was established in 2016 to advance leading edge science from Oxford University and the Karolinska Institute. We work to develop innovative exosome therapeutics for diseases with significant unmet medical need.
Backed by leading venture capital groups and leveraging a comprehensive dominant intellectual property portfolio Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of rare and severe diseases with limited treatment options for patients and their families.
We have already recruited exceptional people working in multidisciplinary teams, sharing our mission to transform how we treat rare diseases. Why not join our team and make your contribution to our journey ahead.
Birth of the term 'exosome' through the discovery of shed vesicles from cells.
First description by Harding et al, of maturing reticulocytes releasing vesicles into the extracellular space
Landmark discovery by Raposo et al, describing vesicle-meditated transfer of antigens.
First of several discoveries describing the transfer of mRNA and miRNA by Evs.
One of the most cited articles in the journal's history, showing that engineered exosomes are capable of delivering siRNA to the brain.
Founded in Oxford, by Dr. Per Lundin, Professor Matthew Wood, and Dr. Samir El Andaloussi. The company was spun out from Oxford University and the Karolinska Institute in Sweden.
£10 million raised from Oxford Sciences Innovation.
Evox entered into two R&D pharma collaborations with global pharmaceutical companies.
£35.5 million raised, bringing new investors into Evox Therapeutics. Redmile Group, Google Ventures, Cowen Healthcare Ventures, Panacea Ventures, and Borealis Ventures.
Evox moved into the Medawar building.
Takeda and Evox Therapeutics sign multi-target Rare Disease collaboration.
Lilly and Evox Therapeutics announce a multi-target RNAi and antisense research collaboration and license agreement.
At Evox, values are at the heart of how we operate, how we behave, and how we will drive the growth of our exciting company.
We developed the values internally with all our employees, ones which we could all identify and work with.
Cover offered is for new and pre-existing conditions
Cover offered is 4 x base salary
25 days holiday plus bank holidays
Employer contribution 5%, employee minimum contribution 5%, however, more than 5% can be contributed if you wish
Bonus is payable based on a combination of corporate and personal performance
Stock Options are issued once the probationary period is passed
I love working at Evox because of the commitment to excellence, clear vision and values and flexible working
I love working at Evox because I thoroughly enjoy the innovation process in a supportive and challenging environment
I love working at Evox because of the open and honest communication, and the opportunities for career advancement within a diverse culture
Evox Therapeutics
OX4 4HG Oxford
Directions
careers@evoxtherapeutics.com
+44 (0)1865 819140
View page
Let’s recruit together and find your next colleague.
Career site by Teamtailor
